These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9645897)

  • 41. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis.
    Bertrand ME; Ferrari R; Remme WJ; Simoons ML; Fox KM
    Am Heart J; 2015 Dec; 170(6):1092-8. PubMed ID: 26678630
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preoperative β-blocker use in coronary artery bypass grafting surgery: national database analysis.
    Brinkman W; Herbert MA; O'Brien S; Filardo G; Prince S; Dewey T; Magee M; Ryan W; Mack M
    JAMA Intern Med; 2014 Aug; 174(8):1320-7. PubMed ID: 24934977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS).
    Chan JD; Rea TD; Smith NL; Siscovick D; Heckbert SR; Lumley T; Chaves P; Furberg CD; Kuller L; Psaty BM
    Am Heart J; 2005 Sep; 150(3):464-70. PubMed ID: 16169325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    Lindahl B; Baron T; Erlinge D; Hadziosmanovic N; Nordenskjöld A; Gard A; Jernberg T
    Circulation; 2017 Apr; 135(16):1481-1489. PubMed ID: 28179398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benefit of β-blocker treatment for patients with acute myocardial infarction and preserved systolic function after percutaneous coronary intervention.
    Choo EH; Chang K; Ahn Y; Jeon DS; Lee JM; Kim DB; Her SH; Park CS; Kim HY; Yoo KD; Jeong MH; Seung KB
    Heart; 2014 Mar; 100(6):492-9. PubMed ID: 24395980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients.
    Feringa HH; Bax JJ; Boersma E; Kertai MD; Meij SH; Galal W; Schouten O; Thomson IR; Klootwijk P; van Sambeek MR; Klein J; Poldermans D
    Circulation; 2006 Jul; 114(1 Suppl):I344-9. PubMed ID: 16820598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
    Wikstrand J; Wedel H; Castagno D; McMurray JJ
    J Intern Med; 2014 Feb; 275(2):134-43. PubMed ID: 24118421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes of β-blocker use in pulmonary arterial hypertension: a propensity-matched analysis.
    Bandyopadhyay D; Bajaj NS; Zein J; Minai OA; Dweik RA
    Eur Respir J; 2015 Sep; 46(3):750-60. PubMed ID: 26022959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993.
    Koenig W; Löwel H; Lewis M; Hörmann A
    Eur Heart J; 1996 Aug; 17(8):1199-206. PubMed ID: 8869861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery.
    London MJ; Hur K; Schwartz GG; Henderson WG
    JAMA; 2013 Apr; 309(16):1704-13. PubMed ID: 23613075
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group.
    Braun S; Boyko V; Behar S; Reicher-Reiss H; Laniado S; Kaplinsky E; Goldbourt U
    J Am Coll Cardiol; 1998 Mar; 31(4):804-8. PubMed ID: 9525550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic impact of ß-blocker use in patients with stable coronary artery disease.
    Bauters C; Lemesle G; Meurice T; Tricot O; de Groote P; Lamblin N
    Heart; 2014 Nov; 100(22):1757-61. PubMed ID: 24947319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II.
    Krum H; Bailey M; Meyer W; Verkenne P; Dargie H; Lechat P; Anker S
    Cardiology; 2007; 108(1):28-34. PubMed ID: 16960445
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beta-blockers are associated with reduced risk of myocardial infarction after cocaine use.
    Dattilo PB; Hailpern SM; Fearon K; Sohal D; Nordin C
    Ann Emerg Med; 2008 Feb; 51(2):117-25. PubMed ID: 17583376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Yang JH; Hahn JY; Song YB; Choi SH; Choi JH; Lee SH; Kim JH; Ahn YK; Jeong MH; Choi DJ; Park JS; Kim YJ; Park HS; Han KR; Rha SW; Gwon HC
    JACC Cardiovasc Interv; 2014 Jun; 7(6):592-601. PubMed ID: 24947717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
    Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
    Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.
    Puymirat E; Riant E; Aissaoui N; Soria A; Ducrocq G; Coste P; Cottin Y; Aupetit JF; Bonnefoy E; Blanchard D; Cattan S; Steg G; Schiele F; Ferrières J; Juillière Y; Simon T; Danchin N
    BMJ; 2016 Sep; 354():i4801. PubMed ID: 27650822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment?
    Wei L; Flynn R; Murray GD; MacDonald TM
    Pharmacoepidemiol Drug Saf; 2004 Nov; 13(11):761-6. PubMed ID: 15386713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.